Journal of Cardiac Failure
Volume 12, Issue 7 , Pages 507-513 , September 2006

Nesiritide Acutely Increases Pulmonary and Systemic Levels of Nitric Oxide in Patients With Pulmonary Hypertension

  • Kiran K. Khush, MD

      Affiliations

    • From the Division of Cardiology, University of California at San Francisco Medical Center, San Francisco, California
    • ,
  • Teresa De Marco, MD

      Affiliations

    • From the Division of Cardiology, University of California at San Francisco Medical Center, San Francisco, California
    • ,
  • Kalpesh T. Vakharia, BA, BSE

      Affiliations

    • From the Division of Cardiology, University of California at San Francisco Medical Center, San Francisco, California
    • ,
  • Cynthia Harmon, BA

      Affiliations

    • Department of Pediatrics, University of California at San Francisco Medical Center, San Francisco, California
    • ,
  • Jeffrey R. Fineman, MD

      Affiliations

    • Department of Pediatrics, University of California at San Francisco Medical Center, San Francisco, California
    • ,
  • Kanu Chatterjee, MB

      Affiliations

    • From the Division of Cardiology, University of California at San Francisco Medical Center, San Francisco, California
    • ,
  • Andrew D. Michaels, MD, MAS

      Affiliations

    • Division of Cardiology, University of Utah, Salt Lake City, Utah
    • Corresponding Author InformationReprint requests: Andrew D. Michaels, MD, MAS, Division of Cardiology, University of Utah, 30 North 1900 East, Room 4A100, Salt Lake City, UT 84132-2401.

Received 27 March 2006 ,Revised 9 May 2006 ,Accepted 12 May 2006.

References 

  1. Mikhail G, Chester AH, Gibbs JS, Borland JA, Banner NR, Yacoub MH. Role of vasoactive mediators in primary and secondary pulmonary hypertension. Am J Cardiol. 1998;82:254–255
  2. Kaneko FT, Arroliga AC, Dweik RA, Comhair SA, Laskowski D, Oppedisano R, et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med. 1998;158:917–923
  3. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214–221
  4. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732–1739
  5. Ahluwalia A, MacAllister RJ, Hobbs AJ. Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. Basic Res Cardiol. 2004;99:83–89
  6. Lewicki JA, Protter AA. Natriuretic peptide family. In:  Laragh JH,  Brenner BM editor. Hypertension, pathophysiology, diagnosis, and management. New York: Raven; 1995;p. 1029–1053
  7. Protter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens. 1996;9:432–436
  8. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–1540
  9. van der Zander K, Houben AJ, Kroon AA, De Mey JG, Smits PA, de Leeuw PW. Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man. J Hypertens. 2002;20:493–499
  10. Kubo M, Nakaya Y, Matsuoka S, Saito K, Kuroda Y. Atrial natriuretic factor and isosorbide dinitrate modulate the gating of ATP-sensitive K+ channels in cultured vascular smooth muscle cells. Circ Res. 1994;74:471–476
  11. Price JM, Hellermann A. Inhibition of cGMP mediated relaxation in small rat coronary arteries by block of CA++ activated K+ channels. Life Sci. 1997;61:1185–1192
  12. Michaels AD, Chatterjee K, De Marco T. Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension. J Card Fail. 2005;11:425–431
  13. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–367
  14. Maack T. Role of atrial natriuretic factor in volume control. Kidney Int. 1996;49:1732–1737
  15. Kone BC. Molecular biology of natriuretic peptides and nitric oxide synthases. Cardiovasc Res. 2001;51:429–441
  16. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–328
  17. Bolad I, Delafontaine P. Endothelial dysfunction: its role in hypertensive coronary disease. Curr Opin Cardiol. 2005;20:270–274
  18. Kawashima S. The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. Endothelium. 2004;11:99–107
  19. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med. 2005;26:33–65
  20. Higenbottam TW, Laude EA. Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension: Giles F. Filley lecture. Chest. 1998;114:72S–79S
  21. Chen YF, Oparil S. Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci. 2000;320:223–232
  22. Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ. Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol. 2003;139:1289–1296
  23. Papapetropoulos A, Rudic RD, Sessa WC. Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc Res. 1999;43:509–520
  24. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol. 2001;280:F193–F206
  25. Calderone A. The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial and inducible nitric oxide synthases. Heart Fail Rev. 2003;8:55–70
  26. de Frutos S, Saura M, Rivero-Vilches FJ, Rodriguez-Puyol D, Rodriguez-Puyol M. C-type natriuretic peptide decreases soluble guanylate cyclase levels by activating the proteasome pathway. Biochim Biophys Acta. 2003;1643:105–112
  27. Ferrero R, Rodriguez-Pascual F, Miras-Portugal MT, Torres M. Nitric oxide-sensitive guanylyl cyclase activity inhibition through cyclic GMP-dependent dephosphorylation. J Neurochem. 2000;75:2029–2039
  28. Hobbs RE, Miller LW, Bott-Silverman C, James KB, Rincon G, Grossbard EB. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996;78:896–901
  29. Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184–3189
  30. Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:56S–61S

 All decisions regarding this manuscript were made by a guest editor.Supported by a research grant from Scios Inc. (Fremont, California) and grant HL61284 (JRF) from the National Institutes of Health.

PII: S1071-9164(06)00254-5

doi: 10.1016/j.cardfail.2006.05.004

Journal of Cardiac Failure
Volume 12, Issue 7 , Pages 507-513 , September 2006

Article Tools

* Image Usage & Resolution